Co-Diagnostics, Inc. Announces Mosquito Vector Control Training Course in the Dominican Republic

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that their distributor in the Dominican Republic is hosting a workshop on techniques for applying molecular diagnostics to identify disease-carrying mosquitos. The trainings will be conducted by a Co-Diagnostics representative and will include demonstrations of the Company’s polymerase chain reaction (PCR) malaria and ZDC (multiplex Zika-dengue-chikungunya) tests.

Laboratorios Franja S.R.L. is the exclusive distributor of the Company’s products in the Dominican Republic, a country of nearly 12 million people, and will be hosting the demonstrations for its customers and other bioanalysts, veterinarians, and pest control companies. All demonstrations will be conducted on the Company’s CoDx Box™, a magnetic induction thermocycler with software optimized to run Co-Diagnostics’ PCR products. The Company’s assays for malaria and ZDC can be applied to testing mosquito populations to track the presence of infectious diseases in urban and rural areas alike. Vector (the term used to describe an organism that transmits infectious diseases) control and mosquito abatement play a vital role in preventing outbreaks and the spread of mosquito-borne diseases.

Mr. Cameron Gundry, Company Director of Commercialization for Latin America, remarked, “A very clear and distinct need exists for vector control and mosquito abatement in this region. Laboratorios Franja has been a valuable partner in identifying and engaging the customers who would benefit from accurate, affordable molecular diagnostics for these vector-based applications, and this workshop represents several months of outreach and planning.

“Malaria, a mosquito-borne parasite which infects over 2 million people every year and kills nearly 400,000, is both preventable and treatable with early detection, including among the mosquito populations before outbreaks occur. Zika, dengue, and chikungunya are closely-related viruses but important to distinguish between and, like malaria, are more dangerous among the children, the elderly, and pregnant women. We anticipate the interest generated by this workshop will help to further our commercialization efforts in the DR, in a mutually beneficial relationship with the mosquito abatement industry and the public good they provide.”

Laboratorios Franja, an ISO 9001:2015 certified company, has been assisting the Company with all local registration requirements needed to allow import and sale of its products in the Dominican Republic for diagnostic, Research Use, and vector control applications. Laboratories, local health ministries, and other companies interested in using the Company’s technology to improve their vector control efforts should contact Laboratorios Franja at info@laboratoriosfranja.com. More information about the workshop can be found on the event’s brochure, seen here.

About Laboratorios Franja S.R.L.:

Laboratorios Franja is one of the most complete and efficient microbiology laboratories in Santo Domingo, offering distribution and sales of microbiology chemistry (cosmetics, medical equipment and cleaning) products, and food quality/safety, environmental microbiology and physical water chemistry analyses. Laboratorios Franja also markets and distributes high quality culture media, and related state-of-the-art technology. Owned and operated by Frank Reyes, the distributor has a highly qualified team of medical, lab staff and sales staff, and can be found online at www.laboratoriosfranja.com.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with a proprietary diagnostic testing technology and development platform that intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and license the use of its platform to other non-competing developers.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190221005308/en/